HSP can decrease cell damage by stabilizing lysosomes and blocking hydrolytic enzymes (ACP and cathepsin-D) leaking from lysosomes, according to the reversal of hydrolytic enzyme levels during HSP therapy (Khandkar et al., 1996). This evidence concerns the gene CTSD and hereditary spastic paraplegia.